<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Baloxavir: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Baloxavir: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Baloxavir: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="119458" href="/d/html/119458.html" rel="external">see "Baloxavir: Drug information"</a> and <a class="drug drug_patient" data-topicid="119459" href="/d/html/119459.html" rel="external">see "Baloxavir: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F52049505"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Xofluza (40 MG Dose);</li>
<li>Xofluza (80 MG Dose)</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F52044646"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antiviral Agent</span>;</li>
<li>
<span class="list-set-name">Endonuclease Inhibitor</span></li></ul></div>
<div class="block dop drugH1Div" id="F52812470"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1eb6edd9-fc37-44a9-87c3-ceaeb3c4c278">Influenza, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Influenza, treatment: Note:</b> Treatment should ideally begin within 48 hours of symptom onset.</p>
<p style="text-indent:-2em;margin-left:4em;">Children &lt;5 years: Limited data available: Oral: 2 mg/kg once as a single dose; maximum dose: 40 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32516282']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32516282'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Dosing based on experience reported in 36 children &lt;5 years of age who were included in a randomized, double-blind study comparing baloxavir with oseltamivir in children &lt;12 years of age with clinical diagnosis of influenza. Time to alleviation of signs and symptoms was similar between the groups as was incidence of adverse effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32516282']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32516282'])">Ref</a></span>). Due to increased risk of treatment-emergent resistance, FDA approval in this age group was not granted.</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥5 years and Adolescents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32516282','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32516282','lexi-content-ref-manu.1'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:6em;">&lt;20 kg: Oral suspension: Oral: 2 mg/kg once as a single dose.</p>
<p style="text-indent:-2em;margin-left:6em;">20 to &lt;80 kg: Oral suspension, tablet: Oral: 40 mg once as a single dose.</p>
<p style="text-indent:-2em;margin-left:6em;">≥80 kg: Oral: Oral suspension, tablet: Oral: 80 mg once as a single dose.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="61d4b61d-1149-44cf-9bb4-42bb8cca234f">Influenza, postexposure prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Influenza, postexposure prophylaxis: Note:</b> Administer within 48 hours of exposure. Optimal role of baloxavir therapy not defined; baloxavir did not receive FDA approval in ages &lt;5 years because of increased risk of resistance-associated substitutions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32640124','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32640124','lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥5 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">&lt;20 kg: Oral suspension: Oral: 2 mg/kg once as a single dose.</p>
<p style="text-indent:-2em;margin-left:6em;">20 to &lt;80 kg: Oral suspension, tablet: Oral: 40 mg once as a single dose.</p>
<p style="text-indent:-2em;margin-left:6em;">≥80 kg: Oral: Oral suspension, tablet: Oral: 80 mg once as a single dose.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F52045547"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Children ≥5 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl ≥50 mL/minute: There are no dosage adjustments provided in the manufacturer's labeling; however, pharmacokinetic studies show that CrCl ≥50 mL/minute had no clinically important effect on baloxavir (the active metabolite) pharmacokinetics.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &lt;50 mL/minute: There are no dosage adjustments provided in the manufacturer's labeling; has not been studied.</p></div>
<div class="block dohp drugH1Div" id="F52045548"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Children ≥5 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">Mild or moderate hepatic impairment: There are no dosage adjustments provided in the manufacturer's labeling; however, pharmacokinetic studies show that moderate hepatic impairment had no clinically important effect on baloxavir pharmacokinetics.</p>
<p style="text-indent:-2em;margin-left:4em;">Severe hepatic impairment: There are no dosage adjustments provided in the manufacturer's labeling; has not been studied.</p></div>
<div class="block doa drugH1Div" id="F52044739"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="119458" href="/d/html/119458.html" rel="external">see "Baloxavir: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="536ebd56-c1bb-4a0c-8efb-299f4ee9f3fb">Influenza, seasonal, postexposure prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Influenza, seasonal, postexposure prophylaxis: Oral:</b></p>
<p style="text-indent:-2em;margin-left:4em;">&lt;80 kg: 40 mg as a single dose within 48 hours of influenza exposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32640124']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32640124'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">≥80 kg: 80 mg as a single dose within 48 hours of influenza exposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32640124']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32640124'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8e42eebf-1cc9-4d9c-8452-1459db020923">Influenza, seasonal, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Influenza, seasonal, treatment:</b>
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:4em;">&lt;80 kg: 40 mg as a single dose within 48 hours of onset of influenza symptoms.</p>
<p style="text-indent:-2em;margin-left:4em;">≥80 kg: 80 mg as a single dose within 48 hours of onset of influenza symptoms.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F52044742"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">CrCl ≥50 mL/minute: There are no dosage adjustments provided in the manufacturer's labeling; however, CrCl ≥50 mL/minute had no clinically important effect on baloxavir (the active metabolite) pharmacokinetics.</p>
<p style="text-indent:-2em;margin-left:2em;">CrCl &lt;50 mL/minute: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block doha drugH1Div" id="F52044743"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Mild impairment (Child-Pugh class A): There are no dosage adjustments provided in the manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">Moderate impairment (Child-Pugh class B): There are no dosage adjustments provided in the manufacturer's labeling, however moderate hepatic impairment had no clinically important effect on baloxavir (the active metabolite) pharmacokinetics.</p>
<p style="text-indent:-2em;margin-left:2em;">Severe impairment (Child-Pugh class C): There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block adr drugH1Div" id="F52046110"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%: Gastrointestinal: Diarrhea (children: 5%), vomiting (children: 5%)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Erythema multiforme, skin rash, urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Colitis, hematochezia, melena</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylactic shock, anaphylaxis, angioedema, hypersensitivity reaction, nonimmune anaphylaxis</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Abnormal behavior, delirium, hallucination</p></div>
<div class="block coi drugH1Div" id="F52039726"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity (eg, anaphylaxis, angioedema, urticaria, erythema multiforme) to baloxavir marboxil or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F52044727"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Concerns related to adverse effects:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Bacterial infection: There is no evidence of efficacy of baloxavir marboxil in illnesses (eg, bacterial infections) caused by pathogens other than influenza viruses. Serious bacterial infections may begin with influenza-like symptoms, may coexist with, or occur as an influenza complication. Baloxavir marboxil has not been shown to prevent such complications. Monitor for potential secondary bacterial infections and manage appropriately.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity: Hypersensitivity reactions, including anaphylaxis, angioedema, urticaria, and erythema multiforme have been reported; evaluate and treat accordingly.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F54958134"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Reduced susceptibility to influenza A strains may occur in younger patients who receive baloxavir due to gene mutations of the polymerase acidic (PA) protein; use has been associated with treatment-emergent amino acid substitutions in the PA protein of the influenza RNA polymerase complex (PA/I38X), particularly in influenza A subtype H3N2 isolates, which result in reduced baloxavir susceptibility. The rate of PA substitutions has been reported to be 13.5% to 23.4% in children &lt;12 years of age, occurring more frequently in children &lt;5 years of age (43% of patients; 36/83) as compared to children 5 to &lt;12 years of age (16% of patients; 19/117) (Baker 2020; Hirotsu 2020; manufacturer's labeling). In contrast, a study in adolescent patients (12 to 17 years of age) reported a substitution rate of 9.8% (Portsmouth 2020), and a study that included both adolescent and adult patients reported a substitution rate of 2.2% to 9.7% (Hayden 2018). Children infected with influenza viruses that developed PA substitutions after receipt of baloxavir had delayed symptom resolution (79.8 vs 42.8 hours) and a longer duration of viral shedding (180 vs 24 hours) compared to children with viruses that did not develop substitutions after baloxavir receipt (Hirotsu 2020). In a study of 374 patients who received baloxavir for influenza prophylaxis after a household contact became ill, 5 of 15 patients who developed PA substitutions were ≤10 years of age. While some have reported transmission of PA substitutions among household contacts, in this study PA substitutions were detected only in patients who received baloxavir (Ikematsu 2020).</p></div>
<div class="block prod-avail drugH1Div" id="F55150171"><span class="drugH1">Product Availability</span>
<p style="text-indent:0em;display:inline">Xofluza oral suspension: FDA approved November 2020; anticipated availability currently unknown.</p></div>
<div class="block foc drugH1Div" id="F52044613"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Therapy Pack, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Xofluza (40 MG Dose): 1 x 40 MG (1 ea); 2 x 20 MG (2 ea [DSC])</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Xofluza (80 MG Dose): 1 x 80 MG (1 ea); 2 x 40 MG (2 ea [DSC])</p></div>
<div class="block geq drugH1Div" id="F52044611"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F52184945"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet Therapy Pack</b> (Xofluza (40 MG Dose) Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 x 40 mg (per each): $190.97</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet Therapy Pack</b> (Xofluza (80 MG Dose) Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 x 80 mg (per each): $190.97</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block admp drugH1Div" id="F52614690"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: May administer with or without food. Avoid administering with dairy, calcium-fortified beverages, polyvalent cation-containing laxatives, antacids, or oral supplements (eg, calcium, iron, magnesium, selenium, zinc).</p>
<p style="text-indent:-2em;margin-left:2em;">Oral suspension: May be administered orally or enterally via a feeding tube; must be administered within 10 hours of reconstitution. Do not mix with soft food or liquids. Should be administered while patient is upright; should not be administered while the patient is lying down. Use an accurate measuring device (eg, oral syringe, measuring cup) for oral administration. For administration via a feeding tube, draw up suspension using a compatible enteral syringe; flush with 1 mL of water before and after administration.</p></div>
<div class="block adm drugH1Div" id="F52044745"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral:</b> Initiate within 48 hours of influenza symptom onset or influenza exposure. Administer a single dose with or without food. Avoid administration with dairy products, calcium-fortified beverages, polyvalent cation-containing laxatives, antacids, or oral supplements (eg, calcium, iron, magnesium, selenium, zinc). Oral suspension may be administered orally or enterally via a feeding tube. Use an accurate measuring device (eg, oral syringe) for oral administration. For enteral administration, draw up suspension using an enteral syringe; flush with 1 mL of water before and after administration. Gently swirl suspension to evenly suspend granules (do not shake) just prior to administering the dose.</p></div>
<div class="block sts drugH1Div" id="F52044730"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Oral suspension: Prior to reconstitution, store granules at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). Store in original bottle. Store reconstituted suspension at 20°C to 25°C (68°F to 77°F); discard if not used within 10 hours or stored &gt;25°C (&gt;77°F).</p>
<p style="text-indent:-2em;margin-left:2em;">Tablets: Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). Store in original blister package.</p></div>
<div class="block usep drugH1Div" id="F53571513"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of acute uncomplicated influenza in patients who have been symptomatic for ≤48 hours and who are otherwise healthy (FDA approved in ages ≥5 years and adults) or who are at high risk of developing influenza-related complications (FDA approved in ages ≥12 years and adults); postexposure prophylaxis of influenza following contact with an individual who has influenza (FDA approved in ages ≥5 years and adults).</p></div>
<div class="block cyt drugH1Div" id="F52076253"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP3A4 (minor), P-glycoprotein/ABCB1 (minor), UGT1A3; <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F52076250"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Influenza Virus Vaccine (Live/Attenuated): Antiviral Agents (Influenza A and B) may diminish the therapeutic effect of Influenza Virus Vaccine (Live/Attenuated).  Management: Avoid administration of live influenza virus vaccine (LAIV) within 2 weeks before or 48 hours after administration of antiviral agents. Consider avoiding LAIV if peramivir was given within the last 5 days or baloxavir was given within the last 17 days.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polyvalent Cation Containing Products: May decrease the serum concentration of Baloxavir Marboxil.<i> Risk X: Avoid combination</i></p></div>
<div class="block foi drugH1Div" id="F52044729"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Baloxavir may form a chelate with calcium products, decreasing baloxavir exposure. Management: Avoid coadministration with dairy products</p></div>
<div class="block pri drugH1Div" id="F52044725"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Adverse events were not observed in animal reproduction studies.</p>
<p style="text-indent:0em;margin-top:2em;">Pregnant and postpartum patients (≤2 weeks after delivery) have a higher risk for complications from influenza, including preterm delivery, pneumonia, admission to a hospital or ICU, and maternal and fetal death. Underlying maternal medical conditions increase these risks (ACOG 2018; CDC 2020a).</p>
<p style="text-indent:0em;margin-top:2em;">Due to lack of data, baloxavir marboxil is not recommended for use in pregnant patients (CDC 2020a; CDC 2020b).</p>
<p style="text-indent:0em;margin-top:2em;">An algorithm is available for the treatment of pregnant patients with known or suspected influenza (ACOG 2018). Refer to the Centers for Disease Control and Prevention recommendations for treatment updates based on resistance patterns (ACOG 2018; CDC 2020a).</p></div>
<div class="block mopp drugH1Div" id="F53571511"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Monitor for hypersensitivity reactions.</p></div>
<div class="block pha drugH1Div" id="F52044731"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Baloxavir marboxil is an oral prodrug that is converted to baloxavir, an inhibitor of the endonuclease activity of a selective polymerase acidic (PA) protein, which is required for viral gene transcription, resulting in inhibition of influenza virus replication. Baloxavir has demonstrated antiviral activity against influenza A and B viruses, including strains resistant to standard current antiviral agents (Hayden 2018).</p></div>
<div class="block phk drugH1Div" id="F52044732"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Pharmacokinetic parameters in pediatric patients 5 to 17 years are similar to those observed in adults (Portsmouth 2020; manufacturer's labeling).</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: 1,180 L.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: ~93% to 94%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Baloxavir marboxil is a prodrug; completely converted via UGT1A3 (major) and CYP3A4 (minor) to the active metabolite (baloxavir).</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 79.1 hour.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: 4 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Feces (80.1%); Urine (14.7%; 3.3% as baloxavir).</p></div>
<div class="block phksp drugH1Div" id="F52050016"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Body weight: As weight increases, exposure to baloxavir decreases.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F52765635"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Xofluza</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Xofluza</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Baloxa</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Xofluza</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Xofluza</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Xofluza</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Xofluza</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Xofluza</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Xofluza</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Xofluza</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Xofluza</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Xofluza</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Xofluza</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Xofluza</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Xovluza</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Xofluza</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Xofluza</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Xofluza</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Xofluza</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Xofluza</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Xofluza</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Xofluza</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Xofluza</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Xofluza</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Xofluza</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Xofluza</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Xofluza</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-30247362">
<a name="30247362"></a>American College of Obstetricians and Gynecologists (ACOG). ACOG committee opinion no. 753: assessment and treatment of pregnant women with suspected or confirmed influenza. <i>Obstet Gynecol</i>. 2018;132(4):e169-e173. doi:10.1097/AOG.0000000000002872<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/baloxavir-pediatric-drug-information/abstract-text/30247362/pubmed" id="30247362" target="_blank">30247362</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32516282">
<a name="32516282"></a>Baker J, Block SL, Matharu B, et al. Baloxavir marboxil single-dose treatment in influenza-infected children: a randomized, double-blind, active controlled phase 3 safety and efficacy trial (miniSTONE-2). <i>Pediatr Infect Dis J</i>. 2020;39(8):700-705.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/baloxavir-pediatric-drug-information/abstract-text/32516282/pubmed" id="32516282" target="_blank">32516282</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.1">
<a name="CDC.1"></a>Centers for Disease Control and Prevention (CDC). Influenza antiviral medications: summary for clinicians; 2014. Available at <a href="https://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm" target="_blank">http://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm</a>. Updated December 27, 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.2">
<a name="CDC.2"></a>Centers for Disease Control and Prevention (CDC). Influenza antiviral medications: summary for clinicians. <a href="https://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm" target="_blank">http://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm</a>. Published November 30, 2020a. Accessed December 4, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.3">
<a name="CDC.3"></a>Centers for Disease Control and Prevention (CDC). Recommendations for obstetric health care providers related to use of antiviral medications in the treatment and prevention of influenza. <a href="https://www.cdc.gov/flu/professionals/antivirals/avrec_ob.htm" target="_blank">https://www.cdc.gov/flu/professionals/antivirals/avrec_ob.htm</a>. Published November 30, 2020b. Accessed December 16, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21248682">
<a name="21248682"></a>Fiore AE, Fry A, Shay D, Gubareva L, Bresee JS, Uyeki TM; Centers for Disease Control and Prevention (CDC). Antiviral agents for the treatment and chemoprophylaxis of influenza --- recommendations of the Advisory Committee on Immunization Practices (ACIP). <i>MMWR Recomm Rep</i>. 2011;60(1):1-24.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/baloxavir-pediatric-drug-information/abstract-text/21248682/pubmed" id="21248682" target="_blank">21248682</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30184455">
<a name="30184455"></a>Hayden FG, Sugaya N, Hirotsu N, et al. Baloxavir marboxil for uncomplicated influenza in adults and adolescents. <i>N Engl J Med</i>. 2018;379(10):913-923.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/baloxavir-pediatric-drug-information/abstract-text/30184455/pubmed" id="30184455" target="_blank">30184455</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31538644">
<a name="31538644"></a>Hirotsu N, Sakaguchi H, Sato C, et al. Baloxavir marboxil in Japanese pediatric patients with influenza: safety and clinical and virologic outcomes. <i>Clin Infect Dis</i>. 2020;71(4):971-981.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/baloxavir-pediatric-drug-information/abstract-text/31538644/pubmed" id="31538644" target="_blank">31538644</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32640124">
<a name="32640124"></a>Ikematsu H, Hayden FG, Kawaguchi K, et al. Baloxavir marboxil for prophylaxis against influenza in household contacts. <i>N Engl J Med</i>. 2020;383(4):309-320. doi:10.1056/NEJMoa1915341<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/baloxavir-pediatric-drug-information/abstract-text/32640124/pubmed" id="32640124" target="_blank">32640124</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Portsmouth S, Hayden FG, Kawaguchi K, et al. Baloxavir treatment in adolescents with acute influenza: subgroup analysis from the CAPSTONE-1 trial. <i>J Pediatric Infect Dis Soc</i>. Published online December 19, 2020.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/baloxavir-pediatric-drug-information/abstract-text/33340316/pubmed" id="33340316" target="_blank">33340316</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Xofluza.1">
<a name="Xofluza.1"></a>Xofluza (baloxavir marboxil) [prescribing information]. South San Francisco, CA: Genentech USA Inc; June 2023.</div>
</li></ol></div><div id="topicVersionRevision">Topic 119538 Version 97.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
